A DOUBLE-BLIND, RANDOMISED, 30-WEEK PLACEBO-CONTROLLED PHASE IV STUDY TO ASSESS THE EFFICACY AND SAFETY OF OSILODROSTAT IN PATIENTS WITH HYPERTENSION CAUSED BY HYPERCORTISOLAEMIA DUE TO CUSHING’S SYNDROME

Registry ID

LCI699-RECAG-CL-0615

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE4

Study type

INTERVENTIONAL

Sponsor

RECORDATI RARE DISEASES CANADA INC

Last update

2026-06-17

Conditions

• CUSHING'S DISEASE

View on source registry